Differential response to antidepressants in women with premenstrual syndrome/premenstrual dysphoric disorder: A randomized controlled trial

Archives of General Psychiatry

Volumn 56, Issue 10, 1999, Pages 932-939

  Freeman, Ellen W ^a,c   Rickels, Karl ^a   Sondheimer, Steven J ^a   Polansky, Marcia ^b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^c HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; SEROTONIN UPTAKE INHIBITOR; SERTRALINE;

ADULT; ANALYTIC METHOD; ARTICLE; DRUG EFFECT; DRUG EFFICACY; DYSPHORIA; FEMALE; HUMAN; LUTEAL PHASE; MAJOR CLINICAL STUDY; MENSTRUAL CYCLE; PREMENSTRUAL SYNDROME; RATING SCALE; SEROTONIN RELEASE; SYMPTOMATOLOGY;

ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; ANTIDEPRESSIVE AGENTS, TRICYCLIC; COMORBIDITY; DEPRESSIVE DISORDER; DESIPRAMINE; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; PLACEBOS; PREMENSTRUAL SYNDROME; PSYCHIATRIC STATUS RATING SCALES; SEROTONIN UPTAKE INHIBITORS; SERTRALINE; TREATMENT OUTCOME;

EID: 0032851143     PISSN: 0003990X     EISSN: None     Source Type: Journal    
DOI: 10.1001/archpsyc.56.10.932     Document Type: Article

References (41)

1. American College of Obstetricians and Gynecologists Committee on Gynecologic Practice. ACOG committee opinion: premenstrual syndrome. Int J Gynaecol Obstet. 1995;50:80-84.
2. Logue CM, Moos RH. Perimenstrual symptoms: prevalence and risk factors. Psychosom Med. 1986;48:388-414.
3. Ramcharan S, Love EJ, Fick GH, Goldtien A. The epidemiology of premenstrual symptoms in a population-based sample of 2650 urban women: attributable risk and risk factors. J Clin Epidemiol. 1992;45:377-392.
4. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. Washington, DC: American Psychiatric Association; 1994.
5. Steiner M, Steinberg S, Stewart D, Carter D, Berger C, Reid P, Grover D, Streiner D, for the Canadian Fluoxetine Premenstrual Dysphoria Collaborative Study Group. Fluoxetine in the treatment of premenstrual dysphoria. N Engl J Med. 1995;332: 1529-1534.
6. Menkes DB, Taghavi E, Mason PA, Spears GF, Howard RC. Fluoxetine treatment of severe premenstrual syndrome. BMJ. 1992;305:346-347.
7. Menkes DB, Taghavi E, Mason PA, Howard RC. Fluoxetine's spectrum of action in premenstrual syndrome. Int Clin Psychopharmacol. 1993;8:95-102.
8. Stone AB, Pearlstein TB, Brown WA. Fluoxetine in the treatment of late luteal phase dysphoric disorder. J Clin Psychiatry. 1991;52:290-293.
9. Wood SH, Mortola JF, Chan YF, Moossazadeh F, Yen SS. Treatment of premenstrual syndrome with fluoxetine: a double-blind, placebo-controlled, crossover study. Obstet Gynecol. 1992;80:339-344.
10. Ozeren S, Corakci A, Yucesoy I, Mercan R. Erhan G. Fluoxetine in the treatment of premenstrual syndrome, Eur J Obstet Gynecol Reprod Biol. 1997;73:167-170.
11. Su TP, Schmidt PJ, Danaceau MA, Tobin MD, Rosenstein DL, Murphy DL, Rubinow DR. Fluoxetine in the treatment of premenstrual dysphoria. Neuropsychopharmacology. 1997;16:346-356.
12. Pearlstein TB, Stone AB, Lund SA, Scheft H, Zlotnick C, Brown WA. Comparison of fluoxetine, bupropion and placebo in the treatment of premenstrual dysphoric disorder. J Clin Psychopharmacol. 1997;17:261-266.
13. Diegoli MSC, da Fonseca AM. Diegoli CA, Pinotti JA. A double-blind trial of four medications to treat severe premenstrual syndrome. Int J Gynaecol Obstet. 1998; 62:63-67.
14. Yonkers KA, Halbreich U, Freeman E, Brown C, Endicott J, Frank E, Parry B, Stout A, Stone A, Harrison W, for the Sertraline Premenstrual Dysphoric Collaborative Study Group. Symptomatic improvement of premenstrual dysphoric disorder with sertraline treatment: a randomized controlled trial. JAMA. 1997;278:983-988.
15. Halbreich U, Smoller J. Intermittent luteal phase sertraline treatment of dysphoric premenstrual syndrome. J Clin Psychiatry. 1997;58:399-402.
16. Young SA, Hurt PH, Benedek DM, Howard RS. Treatment of premenstrual dysphoric disorder with sertraline during the luteal phase: a randomized, double-blind, placebo-controlled crossover trial. J Clin Psychiatry. 1998;59:76-80.
17. Eriksson E, Hedberg MA, Andersch B, Sundblad C. The serotonin reuptake inhibitor paroxetine is superior to the noradrenaline reuptake inhibitor maprotiline in the treatment of premenstrual syndrome. Neuropsychopharmacology. 1995; 12:167-176.
18. Sundblad C, Modigh K, Andersch B, Eriksson E. Clomipramine effectively reduces premenstrual irritability and dysphoria: a placebo-controlled trial. Acta Psychiatr Scand. 1992;85:39-47.
19. Sundblad C. Medberg MA, Eriksson E. Clomipramine administered during the luteal phase reduces the symptoms of premenstrual syndrome: a placebo-controlled trial. Neuropsychopharmacology. 1993;9:133-145.
20. Taghavi E, Menkes DB, Howard RC, Mason PA, Shaw JP, Spears GF. Premenstrual syndrome: a double-blind controlled trial of desipramine and methylscopolamine. Int Clin Psychopharmacol. 1995;10:119-122.
21. Harrison WM, Endicott J, Nee JC. Treatment of premenstrual depression with nortriptyline: a pilot study. J Clin Psychiatry. 1989;50:136-139.
22. First MB, Spitzer RL, Gibbon M, Williams JBW. Structured Clinical Interview for DSM-IV Axis I Disorders-Patient Version 2.0 (SCID-1/P). New York: Biometrics Research Dept, New York State Psychiatric Institute; 1995.
23. Hamilton M. A rating scale for depression. J Neurol Neurosurg. 1960;23:56-62.
24. Freeman EW, DeRubeis RJ, Rickels K. Reliability and validity of a daily diary for premenstrual syndrome. Psychiatry Res. 1996;65:97-106.
25. Freeman EW, Rickels K, Sondheimer SJ, Polansky M. A double-blind trial of oral progesterone, alprazolam, and placebo in treatment of severe premenstrual syndrome. JAMA. 1995;274:51-57.
26. Freeman EW, Rickels K, Sondheimer SJ, Wittmaack FM. Sertraline versus desipramine in the treatment of premenstrual syndrome: an open-label trial. J Clin Psychiatry. 1996;57:7-11.
27. Guy W. ECDUE Assessment Manual for Psychopharmacology, Revised. Rockville, Md: US Dept of Health, Education, and Welfare; 1976. Publication ADM 76-338.
28. Endicott J, Nee J, Harrison W, Blumenthal R. Quality of life enjoyment and satisfaction questionnaire: a new measure. Psychopharmacol Bull. 1993;29:321-326.
29. Dott SG, Walling DP, Bishop SL, Bucy JE, Folkes CC. The efficacy of short-term treatment for improving quality of life: a pilot study. J Nerv Ment Dis. 1996;184: 507-509.
30. Koscis JH, Zisook S, Davidson J, Shelton R, Yonkers K, Hellerstein DJ, Rosenbaum J, Halbreich U. Double-blind comparison of sertraline, imipramine, and placebo in the treatment of dysthymia: psychosocial outcomes. Am J Psychiatry. 1997;154:390-395.
31. SAS/STAT Guide for Personal Computers: Version 6.04. Cary, NC: SAS Institute Inc; 1990.
32. Nelson C. Use of desipramine in depressed inpatients. J Clin Psychiatry. 1984; 45:10-16.
33. Kleber RJ. A double-blind comparative study of desipramine hydrochloride and diazepam in the control of mixed anxiety/depression symptomatology. J Clin Psychiatry. 1979;40:165-170.
34. Rojansky N, Halbreich U, Zander K, Barkai A, Goldstein S. Imipramine receptor binding and serotonin uptake in platelets of women with premenstrual changes. Gynecol Obstet Invest. 1991;31:146-152.
35. Ashby CR Jr, Carr LA, Cook CL, Steptoe MM, Franks DD. Alteration of 5-ht uptake by plasma fractions in the premenstrual syndrome. J Neural Transm. 1990; 79:41-50.
36. Halbreich U, Tworek H. Altered serotonergic activity in women with dysphoric premenstrual syndromes. Int J Psychiatry Med. 1993;23:1-27.
37. Rapkin AJ, Edelmuth E, Chang LC, Reading AE, McGuire MT, Su TP. Wholeblood serotonin in premenstrual syndrome. Obstet Gynecol. 1987;70:533-537.
38. Su TP, Schmidt PJ, Danaceau M, Murphy DL, Rubinow DR. Effect of menstrual cycle phase on neuroendocrine and behavioral responses to the serotonin agonist m-chlorophenylpiperazine in women with premenstrual syndrome and controls. J Clin Endocrinol Metab. 1997;82:1220-1228.
39. Freeman EW, Rickels K, Arredondo F, Kao LC, Pollack SE, Sondheimer SJ. Fuller half-cycle treatment of severe premenstrual syndrome with a serotonergic antidepressant. J Clin Psychopharmacol. 1999;19:3-8.
40. Jermain DM, Preece CK, Sykes RL, Kuehl TJ, Sulak PJ. Luteal phase sertraline treatment for premenstrual dysphoric disorder: results of a double-blind, placebo-controlled, crossover study. Arch Fam Med. 1999;8:328-332.
41. Wikander I, Sundblad C, Andersch B, Dagnell I, Zylberstein D, Bengtsson F, Eriksson E. Citalopram in premenstrual dysphoria: is intermittent treatment during luteal phases more effective than continuous medication throughout the menstrual cycle? J Clin Psychopharmacol. 1998;18:390-398.